Tirzepatide Dosage Guide
93/100 confidenceComplete guide to Tirzepatide dosing protocols, administration methods, and safety considerations for research purposes.
Dosage Overview
Dose per Injection
2.5 mg – 15 mg
Frequency
Once per week
Route
subcutaneous
Cycle Length
16–52 weeks
Detailed Dosage Information
For weight management (Zepbound)
start at 2.5 mg weekly for 4 weeks.
Escalate to 5 mg for 4 weeks, then 7.5 mg for 4 weeks, then 10 mg.
May increase to 12.5 mg, then maximum 15 mg weekly.
For type 2 diabetes (Mounjaro)
same escalation schedule, maintenance at 5 mg, 10 mg, or 15 mg based on glycemic response.
Administration Method
Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Pre-filled single-dose pen — no reconstitution needed. Store refrigerated before first use; may be stored at room temperature (up to 86°F) for up to 21 days. Administer on the same day each week; may change the day if the last dose was given 3+ days prior.
Research Backing
SURMOUNT 1-5 trials (weight management), SURPASS 1-5 trials (T2D). SURMOUNT-1 showed 20.9% weight loss at 15 mg dose. FDA-approved 2022 (Mounjaro), 2023 (Zepbound).
Side Effects to Monitor
Very common (>10%): nausea (up to 33%), diarrhea (up to 25%), decreased appetite, vomiting, constipation, dyspepsia, abdominal pain. Generally milder GI side effects than semaglutide, potentially due to GIP receptor co-activation. Common (1-10%): injection site reactions, fatigue, hypersensitivity reactions, GERD, hair loss, eructation.
Safety Considerations & Risks
Black box warning: thyroid C-cell tumors in rodent studies. Contraindicated in patients with personal/family history of MTC or MEN 2. Risk of pancreatitis, gallbladder events, hypoglycemia (especially with insulin/sulfonylureas). Muscle loss concerns similar to semaglutide. Not studied in patients with gastroparesis — avoid in severe GI motility disorders. Contraindicated in pregnancy.